The University of Bristol and spin-out firm Imophoron are set to assess Covid-19 vaccine candidates in-vivo in a pre-clinical programme.
Imophoron has generated several candidates based on its ADDomer vaccine platform, a synthetic, self-assembling, virus-like particle (VLP).
The company collaborated with the University of Bristol’s Covid-19 Emergency Research (UNCOVER) Group and will lead the vaccine development.
Preclinical tests are expected to begin within weeks. Imophoron founder and CEO Frederic Garzoni said: “We have optimised our process and can now design and roll-out potential vaccines in about two weeks, ready for testing. “With our technology, we hope to contribute to resolving the major health and economic threats caused by
Read more on pharmaceutical-technology.com